Fudan University Shanghai Cancer Center
Shanghai, China
Location status: Recruiting
NCT Number: NCT06281405
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, organ or anal preservation rate, 3-year DFS rate, etc.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 2
Shanghai, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PD-1 inhibitor (Toripalimab): 240mg d1 q3w
Other names: Toripalimab
Capecitabine: 1000mg/m2 bid d1-14 q3w
Short-course radiotherapy: 25Gy/5Fx
Oxaliplatin 130mg/m2 d1 q3w
Time frame: 1 month after the surgery or the decision of W&W
Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.
Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy
Rate of chemotherapy, radiotherapy and immunotherapy related adverse events
Time frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.
3 year organ or anal preservation rate
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
Rate of 3 year disease free survival
Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.
Rate of 3 year local recurrence free survival
Time frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.
Rate of 3 year distant metastasis free survival
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months.
Rate of 3 year overall survival
Time frame: The surgical complications were assessed within 3 months after the surgery.
Rate of surgical complications, such as intraoperative hemorrhage, anastomotic leakage, intestinal obstruction, etc.
Contact information is provided by the study sponsor or research team.
Yaqi Wang, MD
CONTACT
Zhen Zhang, MD
CONTACT
Fudan University
Other
A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)
Acronym: TORCH-iTNT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07150949
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06802666
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Hubei, China
View Trial DetailsNCT04815694
Locally Advanced Rectal Cancer, Neoadjuvant Chemoradiotherapy
Roma, Italy
View Trial DetailsNCT06204094
Colorectal Neoplasms, Digestive System Diseases
Jinhua, Zhejiang, China
View Trial Details